CN1207297C - 晶体治疗剂 - Google Patents

晶体治疗剂 Download PDF

Info

Publication number
CN1207297C
CN1207297C CNB018133924A CN01813392A CN1207297C CN 1207297 C CN1207297 C CN 1207297C CN B018133924 A CNB018133924 A CN B018133924A CN 01813392 A CN01813392 A CN 01813392A CN 1207297 C CN1207297 C CN 1207297C
Authority
CN
China
Prior art keywords
ethyl
methoxyethyl
ethoxy
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018133924A
Other languages
English (en)
Chinese (zh)
Other versions
CN1444585A (zh
Inventor
L·J·哈里斯
R·A·斯托利
A·S·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN1444585A publication Critical patent/CN1444585A/zh
Application granted granted Critical
Publication of CN1207297C publication Critical patent/CN1207297C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CNB018133924A 2000-07-28 2001-07-18 晶体治疗剂 Expired - Fee Related CN1207297C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0018656.9 2000-07-28
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
GB0106464.1 2001-03-15

Publications (2)

Publication Number Publication Date
CN1444585A CN1444585A (zh) 2003-09-24
CN1207297C true CN1207297C (zh) 2005-06-22

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018133924A Expired - Fee Related CN1207297C (zh) 2000-07-28 2001-07-18 晶体治疗剂

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU2001272690B2 (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1742950B1 (en) 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
DK1881985T3 (da) * 2005-05-12 2011-02-14 Pfizer Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003039T2 (tr) * 1998-04-20 2001-01-22 Pfizer Inc. Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
ECSP034454A (es) 2003-03-10
PL365133A1 (en) 2004-12-27
UY26854A1 (es) 2002-02-28
MX233602B (es) 2006-01-10
KR100457937B1 (ko) 2004-11-20
EA004681B1 (ru) 2004-06-24
PT1305314E (pt) 2005-04-29
CA2417264A1 (en) 2002-02-07
ATE286901T1 (de) 2005-01-15
HK1055954A1 (en) 2004-01-30
CZ2003126A3 (cs) 2004-02-18
SV2001000570A (es) 2002-09-03
HUP0302982A2 (hu) 2003-12-29
MY117831A (en) 2004-08-30
BG107266A (bg) 2003-07-31
AU2001272690B2 (en) 2005-12-08
DE60108398T2 (de) 2005-12-22
NO20030416D0 (no) 2003-01-27
UA72631C2 (uk) 2005-03-15
ZA200301457B (en) 2004-04-28
EE200300045A (et) 2004-12-15
CA2417264C (en) 2007-06-12
DZ3364A1 (fr) 2002-02-07
MA26931A1 (fr) 2004-12-20
WO2002010171A1 (en) 2002-02-07
HRP20030061A2 (en) 2003-04-30
GEP20053494B (en) 2005-04-25
EA200300079A1 (ru) 2003-06-26
PE20020277A1 (es) 2002-05-11
TWI285643B (en) 2007-08-21
MXPA03000856A (es) 2003-06-06
YU4703A (sh) 2006-01-16
NO20030416L (no) 2003-02-05
EP1305314A1 (en) 2003-05-02
AP1400A (en) 2005-04-28
AP2001002234A0 (en) 2001-09-30
IL153226A0 (en) 2003-07-06
DOP2001000217A (es) 2002-10-30
PA8523501A1 (es) 2002-10-24
KR20030016430A (ko) 2003-02-26
HUP0302982A3 (en) 2005-01-28
SK572003A3 (en) 2004-05-04
PH12001001922B1 (en) 2006-11-21
NZ523226A (en) 2003-07-25
IS6626A (is) 2002-11-18
CN1444585A (zh) 2003-09-24
EP1305314B1 (en) 2005-01-12
AR032628A1 (es) 2003-11-19
TNSN01112A1 (fr) 2005-11-10
AU7269001A (en) 2002-02-13
NO324220B1 (no) 2007-09-10
IN2002MU01649A (enExample) 2004-12-11
JP2004505087A (ja) 2004-02-19
DE60108398D1 (de) 2005-02-17
BR0112734A (pt) 2004-08-10
ES2231521T3 (es) 2005-05-16
OA12337A (en) 2006-05-15

Similar Documents

Publication Publication Date Title
CN102939289B (zh) 取代的5-氟-1h-吡唑并吡啶类化合物及其用途
CN115554300B (zh) 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途
US20060287528A1 (en) Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
JP6618530B2 (ja) 置換ｎ，２−ジアリールキノリン−４−カルボキサミドおよび抗炎症剤としてのその使用
TW201120033A (en) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN1639164A (zh) 含氮杂环化合物
EP3209652B1 (en) Tricyclic atropisomer compounds
CN107428691A (zh) 取代的n‑双环‑2‑芳基喹啉‑4‑甲酰胺及其用途
JP3204456B2 (ja) ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
CN1207297C (zh) 晶体治疗剂
JP2013512216A (ja) 置換ピラゾロピリミジン類の結晶形
CN1214029C (zh) 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
US6350751B1 (en) Therapeutic agents
WO2004072079A1 (en) Hydrated and anhydrous sildenafil hemi-citrate compound
US20020040140A1 (en) Crystalline therapeutic agent
HK1055954B (en) Crystalline therapeutic agent
EP1220855B1 (en) Anhydrous salt
AU2001272690A1 (en) Crystalline therapeutic agent
US20040235857A1 (en) Crystalline therapeutic agent
HK40085266B (zh) 二氮杂双环取代的咪唑并嘧啶及其用於治疗呼吸障碍的用途
HK1078574B (en) Pyrazolo [4,3-d] pyrimidine derivatives
HK1078574A1 (zh) 吡唑并[4，3-d]嘧啶衍生物
HK1069577B (en) Pyrazolo [4,3-d] pyrimidine derivatives
HK1062299A (en) Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee